Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Aliskiren review completed

The European Medicines Agency (EMA) has completed a review of aliskiren (Rasliez®) by recommending new contraindications and warnings. It is expected that prescribing information will be updated to reflect this new advice.

The ALTITUDE Study was recently stopped early due to a higher rate of adverse events occurring in the treated study participants. Initially, the EMA recommended against using aliskiren in combination with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) in patients with diabetes.

This advice has now been extended to include a contraindication in patients with moderate to severe renal impairment and a warning that the combination of aliskiren and ACEI or ARB should be carefully considered in all other patients.

Action: Clinicians should be aware of this extended advice and implement any necessary change in practice. Patients should be reviewed where appropriate and alternative treatments considered.

Share 'Aliskiren review completed' on Email Share 'Aliskiren review completed' on Delicious Share 'Aliskiren review completed' on Digg Share 'Aliskiren review completed' on Facebook Share 'Aliskiren review completed' on Google+ Share 'Aliskiren review completed' on reddit Share 'Aliskiren review completed' on StumbleUpon Share 'Aliskiren review completed' on Twitter

atomic-wealth

No Comments to “Aliskiren review completed”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,208 spam comments.

atomic-wealth
fond-illness
summer